A judge in New Jersey recently dismissed two product liability suits that had been filed against the pharmaceutical company Wyeth concerning its hormone replacement treatments.

 

Judge Jamie Happas of the New Jersey Superior Court granted the motion filed by Wyeth for summary judgments, ruling that the plaintiffs had not provided the specific type of evidence required to proved that the labeling, which had received U.S. Food and Drug Administration approval, did not provide adequate warning of the risks associated with the treatments.

 

In each case, the plaintiff alleged that her use of Wyeth’s Prempro and Premarin hormone therapy products caused them to develop breast cancer.

 

The suits had been scheduled to go to trial later in the year.

Be the first to comment!
Post a Comment